<DOC>
	<DOCNO>NCT00030108</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : This phase I trial study side effect best dose ixabepilone treating young patient relapsed refractory solid tumor leukemia .</brief_summary>
	<brief_title>Ixabepilone Treating Young Patients With Solid Tumors Leukemia That Have n't Responded Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) ixabepilone young patient refractory solid tumor ( close accrual 10/4/2007 ) relapse refractory leukemia . - Determine toxicity spectrum drug patient . - Determine plasma pharmacokinetics drug patient . - Determine pharmacodynamics drug patient . - Assess nerve growth factor level , initiation drug , potential surrogate marker development peripheral neuropathy patient . Secondary - Determine response patient treated drug . - Compare tolerability , toxicity profile , MTD , DLT , pharmacokinetics , pharmacodynamics drug young patient treat study v adult solid tumor ( close accrual 10/4/2007 ) treat ongoing Medicine Branch , NCI , phase I study . - Assess safety tolerability ixabepilone solid tumor MTD ( expand leukemia cohort ) . - Evaluate plasma pharmacokinetics young patient refractory relapse leukemia . - Evaluate extent tubulin polymerization leukemic blast baseline treatment ixabepilone ex-vivo . - Compare effect tubulin polymerization leukemic blast ixabepilone versus paclitaxel ex-vivo without presence potent P-glycoprotein inhibitor . - Evaluate activity know drug transporter drug-resistant leukemias leukemic blast . OUTLINE : This multicenter , dose-escalation study . Patients receive ixabepilone IV 1 hour day 1-5 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos ixabepilone maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Intrapatient dose escalation one dose level enrollment dose level allow patient stable respond disease experience benefit therapy ( e.g. , decrease tumor-related pain symptom ) grade 2 great non-hematologic toxicity grade 3 great hematologic toxicity . Additional patient treat MTD . Patients treat MTD may undergo intrapatient dose escalation . PROJECTED ACCRUAL : A maximum 30 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets 1 follow criterion : Histologically confirm solid tumor ( close accrual 10/4/2007 ) relapse failed respond frontline curative therapy potentially curative treatment option exist Curative therapy may include surgery , radiotherapy , chemotherapy , combination modality Eligible tumor type include , limited , follow : Rhabdomyosarcoma Other soft tissue sarcomas Ewing 's sarcoma family tumor Osteosarcoma Neuroblastoma Wilms ' tumor Hepatic tumor Germ cell tumor Primary brain tumor Histologic confirmation may waive brain stem optic glioma Diagnosis relapse refractory leukemia Patients refractory second great relapse leukemia must &gt; 25 % blast bone marrow ( M3 bone marrow ) without active extramedullary disease ( except leptomeningeal disease ) Relapsed failed respond frontline curative therapy potentially curative therapy ( e.g. , radiotherapy , chemotherapy , combination modality ) exist Patients acute promyelocytic leukemia must refractory treatment retinoic acid arsenic trioxide Patients Philadelphia chromosome positive chronic myelogenous leukemia must refractory imatinib No active CNS leukemia ( CNS3 ) PATIENT CHARACTERISTICS : Age : 2 18 ( solid tumor patient [ close accrual 10/4/2007 ] ) 1 21 ( leukemia patient ) Performance status : For patient age 11 21 : Karnofsky 50100 % For patient age 1 10 : Lansky 50100 % Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm^3 ( 20,000/mm^3 leukemia patient ) Hemoglobin ≥ 8.0 g/dL Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT SGPT less 2.5 time ULN No hepatic dysfunction would preclude study Renal : Creatinine normal age OR Creatinine clearance least 60 mL/min No renal dysfunction would preclude study Other : No know severe prior hypersensitivity reaction agent contain Cremophor EL No clinically significant unrelated systemic illness ( e.g. , serious infection organ dysfunction ) would preclude study No grade 2 great preexist sensory neuropathy More 2 month since prior concurrent evidence graft v host disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Recovered therapyrelated acute toxic effect ( leukemia patient ) Prior epoetin alfa allow At least 3 day since prior colonystimulating factor ( e.g. , filgrastim ( GCSF ) , sargramostim ( GMCSF ) , interleukin11 ( IL11 ) ) At least 6 month since prior bone marrow transplantation At least 2 month since prior stem cell transplantation rescue ( leukemia patient ) At least 7 day since prior therapy biological agent hematopoietic growth factor exception erythropoietin More 3 week since prior monoclonal antibody therapy ( leukemia patient ) No concurrent GMCSF IL11 No concurrent immunotherapy Chemotherapy : See Disease Characteristics Recovered therapyrelated acute toxic effect ( leukemia patient ) At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) No concurrent anticancer chemotherapy Endocrine therapy : Concurrent corticosteroid allow control symptom relate tumorassociated edema patient brain tumor Patients brain tumor must stable taper dose corticosteroid 7 day baseline scan perform purpose assess response study therapy Must stable taper dose corticosteroid 7 day prior study entry ( leukemia patient ) Radiotherapy : See Disease Characteristics Recovered therapyrelated acute toxic effect ( leukemia patient ) At least 4 week since prior radiotherapy More 2 week since prior local palliative radiotherapy ( leukemia patient ) More 3 month since prior totalbody irradiation , craniospinal radiotherapy , radiotherapy ≥50 % pelvis ( leukemia patient ) More 6 week since prior substantial bone marrow radiotherapy ( leukemia patient ) No prior extensive radiotherapy ( e.g. , craniospinal irradiation , total body irradiation , radiotherapy half pelvis ) No concurrent anticancer radiotherapy Surgery : See Disease Characteristics Other : Recovered prior therapy At least 30 day since prior investigational anticancer therapy At least 1 week since prior know inhibitor CYP3A4 , include follow : Antibiotics ( i.e. , clarithromycin , erythromycin , troleandomycin ) AntiHIV agent ( i.e , delaviridine , nelfinavir , amprenavir , ritonavir , idinavir , saquinavir , lopinavir ) Antifungals ( i.e. , itraconazole , ketoconazole , fluconazole [ dose &gt; 3mg/kg/day ] , voriconazole ) Antidepressants ( i.e. , nefaxodone fluovoxamine ) Calcium channel blocker ( i.e. , verapamil diltiazem ) Antiemetics ( i.e. , aprepitant [ Emend® ] ) Miscellaneous agent ( i.e. , amiodarone ) Grapefruit juice No concurrent investigational agent No concurrent St. John 's Wort No concurrent know inhibitor CYP3A4 , include grapefruit juice Concurrent agent induce CYP3A4 allow</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent childhood liver cancer</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>childhood germ cell tumor</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood grade I meningioma</keyword>
	<keyword>childhood grade II meningioma</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>childhood teratoma</keyword>
	<keyword>childhood malignant testicular germ cell tumor</keyword>
	<keyword>childhood malignant ovarian germ cell tumor</keyword>
	<keyword>childhood extragonadal germ cell tumor</keyword>
	<keyword>recurrent childhood malignant germ cell tumor</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood acute basophilic leukemia</keyword>
	<keyword>childhood acute eosinophilic leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>L1 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L2 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L3 childhood acute lymphoblastic leukemia</keyword>
	<keyword>non-T , non-B , cALLa negative childhood acute lymphoblastic leukemia</keyword>
	<keyword>non-T , non-B , cALLa positive childhood acute lymphoblastic leukemia</keyword>
	<keyword>non-T , non-B , cALLa positive , pre-B childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>TdT negative childhood acute lymphoblastic leukemia</keyword>
	<keyword>TdT positive childhood acute lymphoblastic leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
</DOC>